Picture loading failed.

Anti-PDL1 therapeutic antibody (Pre-made Envafolimab biosimilar,Single Domain Variable Fragment;H) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Envafolimab is a novel, single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-188-1mg 1mg 3090
GMP-Bios-ab-188-10mg 10mg 21890
GMP-Bios-ab-188-100mg 100mg 148000
GMP-Bios-ab-188-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PDL1 therapeutic antibody (Pre-made Envafolimab biosimilar,Single Domain Variable Fragment;H)
INN Name Envafolimab
TargetPDL1
FormatSingle Domain Variable Fragment;H
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCna
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesAlphamab;3D Medicines;Sun Yat-Sen University
Conditions Approvedna
Conditions ActiveBiliary cancer;Breast cancer;Solid tumours;Gastric cancer;Gastrointestinal cancer;Hepatitis B;Malignant fibrous histiocytoma;Soft tissue sarcoma
Conditions Discontinuedna
Development Techna